ARPIs for dummies! Plus the Jiffy Stent

GU Cast | Urology Podcast - Ein Podcast von Professor Declan Murphy & Dr Renu Eapen

Podcast artwork

Kategorien:

It has becoming a familiar refrain around the world , and is certainly good news for the prostate cancer community! This week, another androgen receptor pathway inhibitor (ARPI) became reimbursed for men with hormone-sensitive metastatic prostate cancer (mHSPC) in Australia. Darolutamide is already available for men with non-metastatic castration-resistant prostate cancer, and is now also available for men with mHSPC in combination with androgen deprivation therapy and chemotherapy. Therefore...